By Counterforce Health Team in Cresemba (isavuconazole) —

If Cresemba (Isavuconazole) Isn't Approved by UnitedHealthcare in California: Formulary Alternatives & Exception Paths

Answer Box: When Cresemba Gets Denied

If UnitedHealthcare denies Cresemba (isavuconazole) in California, you have three main paths: try a formulary alternative like voriconazole, request a formulary exception with clinical documentation, or file an internal appeal within 65 days. Most denials stem from prior authorization requirements or step therapy—both can be overturned with proper medical necessity documentation. California's Independent Medical Review (IMR) reverses 72% of denials when insurers get it wrong.

Next step: Call UnitedHealthcare member services to confirm your formulary tier and PA requirements, then work with your infectious disease specialist to document why alternatives won't work for your specific case.

Table of Contents

When Alternatives Make Sense

Not every Cresemba denial means you're stuck without treatment. UnitedHealthcare's OptumRx formulary includes several antifungal medications that might work for invasive aspergillosis or mucormycosis, depending on your specific medical situation.

Alternatives make sense when:

  • You haven't tried first-line treatments yet
  • Your infection is susceptible to other azole antifungals
  • You can tolerate monitoring requirements for alternative agents
  • Your infectious disease specialist agrees the alternative is clinically appropriate

Consider pushing for Cresemba instead when:

  • You've failed voriconazole due to side effects or resistance
  • You have significant drug interactions with CYP3A4 inhibitors/inducers
  • You need the convenience of IV-to-oral switching without re-loading
  • Your case involves mucormycosis where amphotericin B is contraindicated
From our advocates: We've seen patients successfully switch to alternatives initially, then use that treatment response data to strengthen their Cresemba appeal later. Sometimes starting treatment—even with a second-choice medication—provides the clinical documentation you need for the preferred option.

UnitedHealthcare's Formulary Alternatives

Based on UnitedHealthcare's 2026 OptumRx formulary, here are the covered antifungal options for invasive fungal infections:

Covered Alternatives by Drug Class

Azole Antifungals:

  • Fluconazole (Tier 1) - Limited spectrum; not effective for aspergillosis or mucormycosis
  • Voriconazole (typically Tier 2-3) - First-line for invasive aspergillosis per IDSA guidelines

Polyene Antifungals:

  • Liposomal amphotericin B (specialty tier) - First-line for mucormycosis
  • Conventional amphotericin B (lower tier) - Higher toxicity profile

Echinocandins:

  • Micafungin, caspofungin (specialty tier) - Often used in combination or for salvage therapy

Coverage Requirements Table

Medication Formulary Tier Prior Authorization Step Therapy Specialty Pharmacy
Fluconazole Tier 1 No No No
Voriconazole Tier 2-3 Often required May apply Sometimes
Liposomal amphotericin B Specialty Required Usually Required
Cresemba (isavuconazole) Tier 3/Specialty Required Usually Required

Source: UnitedHealthcare OptumRx formulary documents

Pros and Cons Overview

Voriconazole (Most Common Alternative)

Pros:

  • Well-established first-line therapy for invasive aspergillosis
  • Extensive clinical data and experience
  • Often preferred by UnitedHealthcare step therapy protocols
  • Available in IV and oral formulations

Cons:

  • Significant drug interactions through CYP3A4 system
  • Visual disturbances in up to 30% of patients
  • QTc prolongation concerns
  • Requires therapeutic drug monitoring
  • Higher rates of liver toxicity

Liposomal Amphotericin B

Pros:

  • First-line for mucormycosis per clinical guidelines
  • Broad antifungal spectrum
  • No significant drug interactions

Cons:

  • Requires IV administration only
  • Nephrotoxicity and infusion reactions
  • Expensive (often exceeds Cresemba costs)
  • Requires specialized monitoring and premedication

Combination Therapy Options

Some patients receive voriconazole plus anidulafungin for severe infections, which shows superior mortality outcomes in network meta-analyses but requires managing two specialty medications.

Exception Strategy

If alternatives aren't appropriate for your case, you can request a formulary exception to get Cresemba covered at a lower tier or without step therapy requirements.

When to Request an Exception

Strong exception cases include:

  • Documented voriconazole intolerance (liver toxicity, visual disturbances, QTc prolongation)
  • Significant drug interactions with current medications
  • Previous treatment failure with formulary alternatives
  • Mucormycosis when amphotericin B is contraindicated
  • Need for reliable IV-to-oral switching in complex care scenarios

Required Documentation for Success

Your infectious disease specialist should provide:

  1. Detailed diagnosis confirmation
    • Culture results or tissue pathology
    • Imaging findings consistent with invasive fungal infection
    • ICD-10 codes (B44.0 for invasive aspergillosis, B46.x for mucormycosis)
  2. Prior treatment documentation
    • Specific medications tried, doses, duration
    • Reasons for discontinuation (side effects, treatment failure, contraindications)
    • Laboratory values showing toxicity if applicable
  3. Clinical rationale for Cresemba
    • Why formulary alternatives are inappropriate
    • Expected treatment duration and monitoring plan
    • Reference to FDA labeling for approved indications
  4. Supporting literature
    • Recent clinical guidelines supporting isavuconazole use
    • Comparative safety data if relevant to your case

Submission Process

For UnitedHealthcare members in California:

  1. Provider submits via UnitedHealthcare Provider Portal or OptumRx system
  2. Include all documentation listed above in initial submission
  3. Request peer-to-peer review if initially denied (increases success rates to 82% per AMA data)
  4. Follow up within 15 business days for non-urgent requests

Switching Logistics

If you need to start an alternative while pursuing Cresemba approval, coordinate carefully with your healthcare team.

Provider Coordination Checklist

  • Infectious disease specialist confirms alternative is clinically appropriate
  • Pharmacy verifies insurance coverage and obtains prior authorization
  • Laboratory schedules baseline monitoring (liver function, drug levels if applicable)
  • Patient education on new medication's side effects and monitoring requirements

Monitoring During Alternative Treatment

For voriconazole:

  • Baseline and periodic liver function tests
  • Therapeutic drug monitoring (target 1-5.5 mcg/mL)
  • Visual symptom assessment
  • ECG monitoring for QTc prolongation

For amphotericin B:

  • Daily electrolyte monitoring initially
  • Kidney function assessment
  • Infusion reaction monitoring and premedication protocols

Documentation for Future Appeals

Keep detailed records of your alternative treatment experience:

  • Response rates and clinical improvement
  • Side effects or tolerability issues
  • Any treatment interruptions or dose modifications
  • Laboratory abnormalities requiring intervention

This documentation strengthens future Cresemba appeals by demonstrating real-world challenges with formulary alternatives.

Re-trying for Cresemba Later

Many patients successfully get Cresemba approved after initially trying alternatives, especially if they document specific problems with first-line treatments.

What to Document During Alternative Treatment

Clinical response data:

  • Time to clinical improvement (or lack thereof)
  • Radiographic changes on follow-up imaging
  • Biomarker trends (galactomannan, beta-D-glucan if applicable)

Tolerability issues:

  • Specific side effects experienced
  • Impact on quality of life or daily functioning
  • Need for dose reductions or treatment interruptions
  • Laboratory abnormalities requiring monitoring

Practical challenges:

  • IV access difficulties with amphotericin B
  • Drug interaction management with voriconazole
  • Monitoring burden and healthcare utilization

Timing Your Re-appeal

Best timing for Cresemba re-appeal:

  • After 30-90 days of alternative treatment with documented issues
  • When clinical response is suboptimal despite adequate alternative therapy
  • If new contraindications to current therapy develop
  • During treatment planning for long-term oral consolidation therapy

Counterforce Health specializes in turning these real-world treatment experiences into compelling medical necessity arguments that address payer-specific criteria and improve approval odds for complex specialty medications.

California Appeals Process

If UnitedHealthcare denies your exception request, California offers strong consumer protections through its Independent Medical Review (IMR) system.

Internal Appeals First

UnitedHealthcare internal appeal requirements:

  • File within 65 days of denial notice
  • Submit via UnitedHealthcare Provider Portal (required since 2023)
  • Include all clinical documentation and exception rationale
  • Timeline: 30 days for standard review, 72 hours for urgent cases

California IMR Process

If internal appeals fail, California's IMR system reverses 72% of medical necessity denials according to DMHC data.

IMR eligibility:

  • UnitedHealthcare denied service as "not medically necessary"
  • You've completed internal grievance process
  • Request filed within 6 months of final internal denial

How to file IMR:

  • Online at healthhelp.ca.gov
  • Call DMHC Help Center: 888-466-2219
  • No cost to patient—insurer pays for review
  • Timeline: 45 days standard, 7 days or less for urgent cases

IMR success factors for antifungal appeals:

  • Board-certified infectious disease specialist documentation
  • Clear medical necessity rationale
  • Evidence that formulary alternatives are inappropriate
  • Reference to established clinical guidelines

FAQ

How long does UnitedHealthcare prior authorization take for antifungal medications in California? Standard PA requests take up to 15 business days. Urgent cases (immediate health risk) are reviewed within 72 hours. Submit complete documentation initially to avoid delays.

What if Cresemba isn't on my specific UnitedHealthcare formulary? You can request a formulary exception with medical necessity documentation. Success rates exceed 80% when clinical rationale is strong and alternatives are contraindicated.

Can I get expedited review for invasive fungal infections? Yes. Invasive aspergillosis and mucormycosis qualify for urgent review due to serious health risks. Request expedited processing when submitting PA or appeals.

Does step therapy apply if I failed voriconazole outside California? UnitedHealthcare should accept prior treatment failures from any location with proper documentation. Include discharge summaries and specialist notes showing previous treatment attempts.

What counts as medical necessity for Cresemba? FDA-approved indications (invasive aspergillosis, mucormycosis) with confirmed diagnosis, plus documentation that formulary alternatives are inappropriate due to contraindications, intolerance, or treatment failure.

How much does Cresemba cost without insurance in California? Wholesale acquisition cost is approximately $394 per IV vial or $1,620 per 14-day oral course. Patient costs vary significantly based on pharmacy and discount programs.

Can my doctor request peer-to-peer review with UnitedHealthcare? Yes. Peer-to-peer review increases approval rates to 82% according to recent surveys. Your specialist can request this during the PA process or appeals.

What if I need Cresemba for off-label use? Off-label uses face higher scrutiny. You'll need extensive documentation including literature support, specialist rationale, and evidence that on-label alternatives aren't appropriate.

About Counterforce Health: Counterforce Health helps patients and providers turn insurance denials into successful appeals by analyzing payer policies, identifying denial reasons, and crafting evidence-backed rebuttals. Their platform specializes in complex specialty medications like antifungals, using payer-specific workflows to improve approval odds and reduce administrative burden.

Sources & Further Reading

Disclaimer: This article provides educational information about insurance coverage and appeals processes. It is not medical advice. Treatment decisions should be made with your healthcare provider based on your individual medical situation. For specific coverage questions, contact UnitedHealthcare member services directly. For assistance with appeals in California, contact the DMHC Help Center at 888-466-2219.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.